Spruce Biosciences stock upgraded by Citizens on promising MPS IIIB therapy
PositiveFinancial Markets

Spruce Biosciences has received an upgrade from Citizens, signaling confidence in its promising therapy for MPS IIIB. This upgrade is significant as it reflects the potential of the therapy to address a rare genetic disorder, which could lead to improved treatment options for patients. Investors are optimistic about the company's future, as advancements in biotech can lead to breakthroughs that not only benefit those affected but also drive market growth.
— Curated by the World Pulse Now AI Editorial System









